High-density lipoprotein: why all the fuss?

Area of Science:

• Cardiovascular Science
• Biochemistry
• Pharmacology

Background:

• Coronary heart disease (CHD) treatments often aim to increase high-density lipoprotein (HDL)-cholesterol.
• The failure of CETP inhibitor torcetrapib highlights potential issues with this strategy.

Purpose of the Study:

• To review the antiatherosclerotic properties of HDL.
• To evaluate strategies for increasing HDL-cholesterol concentration.
• To propose an alternative therapeutic approach for CHD.

Main Methods:

• Review of existing literature on HDL function and cholesterol-raising therapies.
• Analysis of the relationship between HDL-cholesterol levels and protective functions.
• Critical assessment of the CETP inhibitor torcetrapib's clinical trial outcomes.

Main Results:

• HDL possesses significant antiatherosclerotic properties.
• HDL-cholesterol concentration does not accurately reflect HDL's protective capacity.
• Current strategies focused solely on increasing HDL-cholesterol may be ineffective.

Conclusions:

• Rethinking the approach to CHD treatment is necessary.
• Targeting specific antiatherosclerotic components within HDL particles is a more viable strategy.
• Future research should focus on the functional aspects of HDL rather than just cholesterol levels.